Clinical governance has several pillars, but if you had to name the one that everything else is ultimately in service of, it would be this: Patient Safety.
Last week we talked about information and data governance: who holds your health data, how it’s used, and why that matters. This week, we go to the foundation.
What patient safety actually means in a FemTech context
In regulated healthcare, patient safety is non-negotiable. It is the reason clinical protocols exist, why regulatory frameworks are built the way they are, and why evidence standards are not optional for products that interact with health decisions. The principle is straightforward: before something reaches a patient, it must be held to a standard of care proportionate to the risk it carries.
FemTech developed largely outside that framework, and for understandable reasons. Classifying a product as a wellness tool rather than a medical device allowed founders to move quickly, iterate fast, and reach women who had been waiting a long time for tools built around their health. That flexibility drove real innovation.
But it also created a gap. Products making health-adjacent claims were never required to meet clinical safety standards. And women, often making genuinely consequential health decisions, were using them anyway.
That gap is what patient safety governance is designed to close.
Where the risks actually show up
The risks in FemTech are not abstract. They are specific, documented, and patterned.
Simple cycle tracking apps have demonstrated significant inaccuracies in predicting fertile windows, with downstream consequences for women relying on them for contraception or conception planning. Symptom checkers have missed serious conditions. Algorithms trained on narrow datasets have produced outputs that fail to reflect the diversity of women’s bodies, backgrounds, and clinical presentations.
These are not edge cases. They are recurring failures that point to a structural problem: products making health-relevant claims that were never subjected to the clinical validation those claims require.
Women’s health is genuinely complex. Hormonal dynamics, menstrual disorders, PCOS, perimenopause, reproductive function; these involve nuanced, interacting clinical variables. Translating that complexity into an algorithm requires rigorous validation at every stage. Without it, the product does not simply underperform. It misleads, and a woman making a health decision on the basis of that output bears the consequence.
Why the stakes are higher here
Women came to FemTech, in large part, because mainstream healthcare had already failed them.
They had been dismissed and undertreated, sometimes for decades.
FemTech offered a different proposition: tools designed specifically for women, taking their biology seriously, finally.
That is a significant promise. It is also a significant responsibility.
When FemTech products are inaccurate, unvalidated, or clinically ungrounded, they do not simply fail to help. They risk replacing one form of dismissal with another, this time presented through a clean interface and wrapped in wellness language. For women who came to these tools precisely because they had been failed elsewhere, that is a particular kind of harm.
Patient safety governance exists to ensure that trust is not misplaced.
What strong patient safety practice looks like
Patient safety in FemTech is a continuous clinical commitment that should shape product decisions from the earliest stages of development, not just a launch checklist.
It starts with clearly defined intended use. A product must be precise about what it does, what it does not do, and where the boundary between wellness tracking and clinical guidance lies. That boundary must be communicated to users, not buried in terms of service, but stated plainly.
It requires clinical validation proportionate to the claims being made. Every health-relevant output a product generates should be backed by evidence that is rigorous, reproducible, and transparent. Not compelling testimonials or internally generated metrics, but actual validation against the clinical standard the claim implies.
It demands representative data. An algorithm built on a narrow population will fail everyone outside it, sometimes in ways that are difficult to detect until the harm has occurred. Women of different ages, ethnicities, body types, hormonal profiles, and health histories must be represented in the research underpinning these tools.
And it requires ongoing surveillance. Mechanisms for users to report inaccuracies, flag unexpected outcomes, and raise concerns are not optional features. They are how a clinically responsible product learns and self-corrects after launch.
The baseline, not the ceiling
The FemTech industry does not need to slow down. It needs to build safety into its pace; as a founding principle, not an afterthought.
Clinical credibility is not a constraint on innovation. It is what makes innovation trustworthy, sustainable, and genuinely useful to the women it is designed to serve.
Women deserve tools that work. They deserve transparency about how those tools were built and what they can reliably do. And they deserve to know that the rigour missing from their care in traditional healthcare settings is not being quietly replicated in the technology built to correct it.
That is not a high bar. It is the baseline.
That’s Pillar 6. Next week, we move to Pillar 5 and go even deeper. See you then.
Better Woman Health is published weekly.
Subscribe at betterwomanhealth.com to get it directly in your inbox.
Clinical Credibility Toolkit
The Clinical Credibility Toolkit is a free resource designed for FemTech founders building digital tools for women’s health.
It includes the Clinical Credibility Scorecard, a 28-question assessment that helps you identify gaps in your clinical foundation, evidence strategy, safety architecture, and investor readiness, and the Red Flag Detection Checklist, a 25-question assessment that tells you whether your symptom-tracking app can actually detect and act on medical red flags, not just log them.
If you are preparing to pitch, pursuing healthcare partnerships, or simply want to know where your product stands clinically, start here.
Access the toolkit → app.ayomide.me
Thanks for reading. See you soon!
Dr. Ayomide O.
FemTech Credibility Advisor
Find me on LinkedIn or Book a 1:1 Call
